ACC 25: tirzepatide influences clinical trajectory of patients with HFpEF and obesity
At the American College of Cardiology's 74th Annual Scientific Session in Chicago, further results and analyses were presented from the SUMMIT trial. SUMMIT was the first trial in patients with heart failure with preserved ejection fraction (HFpEF) and obesity with heart failure outcomes as the primary prespecified endpoint. The trial examined the effect of Eli Lilly's glucagon-like peptide-1 receptor agonist (GLP-1RA) tirzepatide, which is marketed as Mounjaro, on the clinical trajectory of patients with HFpEF and obesity. The study had previously identified that tirzepatide was able to reduce the composite of cardiovascular (CV) death and worsening HF events by 38% (P=0.026), an effect that was consistent across various definitions of events.
Obesity often leads to both HFpEF and chronic kidney disease (CKD); CKD may influence the clinical course of obesity-related HFpEF, and incretin-based drugs may influence renal function. This study had dual objectives: 1) to evaluate the influence of CKD on the clinical responses to tirzepatide in patients with obesity-related HFpEF; and 2) to investigate the complexity of tirzepatide-related changes in renal function. Key opinion leaders (KOLs) interviewed by GlobalData have often commented on the need for a therapy that can achieve a broader cardiometabolic approach in treating disease such as CV-kidney metabolic syndrome, which the SUMMIT trial investigates, and tirzepatide's success in treating this broader metabolic syndrome is likely to achieve favourable opinion and uptake from physicians.
The SUMMIT trial randomly assigned 731 patients with HFpEF: chronic HF, left ventricular failure (LVEF) 50% or higher, and body mass index at or above 30kg/m2. Patients were also required to have one of the following: 1) left atrial enlargement; 2) elevated left ventricular (LV) pressures; or 3) NT-proBNP greater than 200pg/mL in sinus rhythm or greater than 600pg/mL in AF. Patients received either placebo or tirzepatide for a median of 104 weeks and were followed for cardiovascular death or worsening heart failure events and for changes in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) after 52 weeks. Because of the confounding variables produced by obesity, and changes in muscle mass, estimated glomerular filtration rate (eGFR) was assessed at the point of randomisation and after 12, 24, and 52 weeks by both creatinine-based and cystatin C–based eGFR calculation formulae. The enrichment criteria used to identify participants at high risk of events included: 6 minute walk test (6MWT) ≥100 and ≤425 meters, KCCQ-CSS ≤80 and HF decompensation within 12 months or eGFR <70m/min/1.73m2. If they met these criteria, participants were then randomised for the duration of double-treatment and follow-up. Patients were on a starting dose of 2.5mg/week, which was uptitrated by 2.5mg every four weeks, as tolerated, until it reached 15mg/week by 20 weeks, and the double-blind treatment was maintained until the last patient completed 52 weeks.
Patients with CKD (based on creatinine or cystatin C) had greater severity of heart failure, as reflected by: 1) worse functional class, KCCQ-CSS scores, and 6-minute walk distance; 2) higher levels of NT-proBNP and cardiac troponin T; and 3) a two-fold increase in the risk of worsening heart failure events. CKD did not influence the effect of tirzepatide to reduce the relative risk of major adverse heart failure events and to improve KCCQ-CSS, quality of life, and functional capacity, but the absolute risk reduction in the primary events was numerically greater in patients with CKD. Regarding renal function assessments, baseline eGFR-cystatin C was consistently approximately 9mL/min/1.73m2 lower than that of eGFR-creatinine, with significant individual variance. Furthermore, tirzepatide increased eGFR at 52 weeks, assessed by both creatinine-based and cystatin C–based formulae, but with considerable discordance in individual patients. Tirzepatide produced a decline in eGFR at 12 weeks with eGFR-creatinine (but not eGFR-cystatin C), and it led to an improvement in eGFR at 52 weeks in all patients (when assessed by cystatin C), but only in patients with CKD (when assessed by eGFR-creatinine).
This substudy from the SUMMIT trial demonstrates long-term tirzepatide improves renal function (both by cystatin C and creatinine), but the measurement of eGFR in patients with obesity receiving GLP-1RAs is likely to be skewed by the effects of fat and muscle mass and the changes in body composition on the synthesis of both cystatin C and creatinine. GlobalData predicts that tirzepatide is likely to be increasingly prescribed for broader cardiometabolic disease and beyond the traditional prescribing of GLP-1RAs for type 2 diabetes (T2D), steadily becoming one of the leading GLP-1 therapies in the market.
"ACC 25: tirzepatide influences clinical trajectory of patients with HFpEF and obesity" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
2 hours ago
- CBS News
Rochester football player who collapsed during game graduates high school
The Beaver County football player who collapsed during a game last year graduated from high school this week. Rochester High School's Carter Mason collapsed on the sidelines after taking a hit in the fourth quarter during a game in October 2024 against Shenango. Mason suffered a brain bleed, his family said. On Thursday, he walked across the stage and received his diploma, a milestone his family said they were not sure he'd ever reach. "How far he came, yeah, it's amazing every single day," his mother, Terri Mason, said. "He makes it look easy," she added. "But it's very depressing, very depressing because he can't do everything he used to do and go places like he used to." After spending nearly three months in the hospital, Carter Mason went home and began occupational, physical and speech therapies. His mom said he still struggles with memory loss. "He doesn't know where he's going," she said. "He doesn't know places, people. So, whenever he goes somewhere, he has to have somebody with him at all times." But she said that her son has not let that stop him from achieving his goals. Terri Mason said he went to school for two to three hours per day to graduate with his classmates. "It was so exciting," she said. "The whole auditorium, I think, was just amazed." Terri Mason said Carter Mason will continue therapy for the next two to three years. But she hopes to get him back to doing things independently, with the goal of a full recovery.
Yahoo
9 hours ago
- Yahoo
Should You Invest $1,000 in Eli Lilly today?
Eli Lilly is a pharma player, but it offers the growth of a tech stock thanks to its weight loss drugs portfolio. The weight loss market could represent a multibillion-dollar opportunity well into the next decade. 10 stocks we like better than Eli Lilly › Eli Lilly (NYSE: LLY) sells a broad range of medicines, from cancer and immunology drugs to treatments for migraine. The pharma giant's presence across several treatment areas has helped it grow earnings over time. But, in recent years, one particular product portfolio has stood out and driven double-digit revenue growth: drugs to help people lose weight. Right now, Lilly sells tirzepatide, commercialized as Mounjaro for type 2 diabetes and as Zepbound for weight loss, though doctors have prescribed either one for patients hoping to shed pounds. Mounjaro and Zepbound each have become blockbusters, bringing in billion-dollar revenue annually. Lilly dominates the weight loss market along with rival Novo Nordisk, but a recent move by Lilly could help it push farther ahead in the coming years. Considering this, should you invest $1,000 in Lilly stock today? Let's find out. So, first, let's talk about Lilly's path so far in this market and what might lie ahead. Lilly's weight loss drugs are part of a class known as dual GIP and GLP-1 receptor agonists. They act on hormonal pathways involved in the digestion process and help control blood sugar levels and appetite. Novo Nordisk's rival drug, semaglutide -- sold as Ozempic for type 2 diabetes and Wegovy for weight loss -- targets only GLP-1 but works in a similar way. Novo Nordisk was first to market with its product, winning approval for Ozempic in 2017, and this offered it time to build a market-leading position. But demand has been so high for such weight loss drugs that Lilly quickly gained share soon after entering the market with Mounjaro in 2022 and then with Zepbound in 2023. In fact, demand has been so strong that these drugs held spots on the U.S. Food and Drug Administration's drug shortage list for quite some time, only exiting the list in recent months. A better supply situation for weight loss drugs isn't due to a drop in demand but instead to increases in manufacturing capacity by both companies. So solid demand for these products still exists -- and is likely to grow. It's important to keep in mind, though, that both Lilly and rivals may face some headwinds in the years to come, and that's why Goldman Sachs Research recently reduced its forecast for global sales of anti-obesity medicines to $95 billion by 2030, from an earlier forecast of $130 billion. This is due to several potential challenges, including lower per-unit prices and weaker reimbursement from certain insurers. But even considering the challenges, "we see a significant growth opportunity for both existing players as well as new entrants into this market," said Goldman analyst Asad Haider. After all, from today's $28 billion market, the forecast figure represents a 239% increase. A look at Lilly's weight loss drug sales shows us this company has the momentum to benefit from this high-growth market. Last year, Mounjaro and Zepbound generated more than $11 billion and $4.9 billion in sales, respectively. And these two products are driving double-digit total sales growth at Lilly -- with a 32% gain in the full year and a 45% gain in the most recent quarter. Now, what may push Lilly past Novo Nordisk -- and keep it far ahead of newer rivals down the road -- is the company's progress on an oral weight loss candidate. Current products are in injectable form, which may be less convenient and even uncomfortable for certain users. Lilly recently reported positive results from a phase 3 trial of its oral candidate, orforglipron, and plans to request approval for use in weight management by the end of the year. Though Novo Nordisk sells an oral form of semaglutide, it involves strict food and water guidelines. The potential Lilly product doesn't, offering it a significant advantage. Now, let's return to our question: Should you invest $1,000 in Lilly right now? The shares are trading for 34 times forward earnings estimates -- that's around the same level as top tech companies such as Amazon and Nvidia, also known for delivering double-digit revenue growth. In fact, since the launch of tirzepatide, Lilly has traded at valuations resembling those of growth stocks. So it may seem pricey to you for a pharmaceutical player. But it's worth keeping in mind that Lilly stands out from the pharma crowd due to its presence in the high-growth market of weight loss drugs, yet at the same time it offers you the stability and dividend growth of a pharma stock. You generally can count on big pharma companies for steady revenue since patients always need their medicines -- regardless of the economic situation. And you can count on Lilly for passive income too, with a forward dividend of $6, representing a dividend yield of 0.8%. Meanwhile, valuation has come down from its peak to levels that look very acceptable for a growth stock. All of this means that, by investing in Lilly, you're getting growth worthy of a tech company along with the safety generally associated with a pharma stock. That makes the stock well worth the price, and a great place to park $1,000 right now. Before you buy stock in Eli Lilly, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Eli Lilly wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $656,825!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $865,550!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Adria Cimino has positions in Amazon. The Motley Fool has positions in and recommends Amazon, Goldman Sachs Group, and Nvidia. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Should You Invest $1,000 in Eli Lilly today? was originally published by The Motley Fool Sign in to access your portfolio
New York Post
11 hours ago
- New York Post
Ozempic makes you twice as likely to develop this debilitating condition — what that really means for your risk
A growing number of Ozempic and Mounjaro users have shared stark warnings after going blind while using GLP-1 drugs. Now a new study is bringing into focus the relationship between diabetic GLP-1 users and the elevated risk of age-related eye disease. But despite seemingly alarming numbers, a doctor explained to The Post why she doesn't actually think it should steer people away from the jab. 3 A 2024 study found that 12% of the US population has taken a GLP-1 drug at some point, with around 6% currently using them. alones – Published in JAMA Ophthalmology, the study was drawn from the health records of nearly 140,000 patients. Researchers found that after one year, GLP-1 users were more than twice as likely to develop neovascular age-related macular degeneration than those who were not taking the drugs. Age-related macular degeneration (AMD) is a disease that gradually damages the macula, the part of your eye's retina responsible for sharp, central vision. As it worsens, people find it increasingly difficult to see things directly in front of them, while their peripheral vision remains largely unaffected. In older people, AMD is a leading cause of irreversible blindness. The study found the risk percentage was 0.2% in GLP-1 users and 0.1% in nonusers. Nearly 20 million adults in the US are living with AMD, which comes in two types. The slower-moving dry AMD makes up about 80% of cases. It occurs when the macula gets thinner with age, often due to the buildup of yellow protein deposits known as drusen, according to the American Academy of Ophthalmology. Wet AMD, also known as neovascular AMD (nAMD), while less common, is far more aggressive, causing rapid and severe vision loss. In this form, the macula's function is compromised by the growth and leakage of abnormal blood vessels beneath the retina. The condition is typically treated with frequent injections to restore or stabilize vision. 3 Kaden notes that while there is cause for concern, headlines will amplify what she believes is a relatively low risk Northwell Foundation 'What researchers in this latest study were looking for specifically was whether or not these were people who converted from the dry form of macular degeneration, which is where you don't have abnormal blood vessels to the wet form, which is when you do,' Dr. Talia Kaden, director of the Northwell Health retina fellowship told the Post. But Kaden noted that while there is cause for concern, she actually believes there a relatively low risk. 'We're talking about a handful of patients who might have an increase in retinopathy compared to the millions of patients on these medications.' Dr. Talia Kaden 'That 2X number is really powerful, but when you look at the raw data, I don't think it's quite as strong a punch. I don't think that number should be a reason for people not to be on these drugs. I do think, though, it is worth continuing to look into,' she said. This study adds to a growing body of research documenting vision problems in patients using GLP-1 drugs. A review published earlier this year in JAMA Ophthalmology uncovered at least nine cases of patients who experienced vision loss after taking semaglutide or tirzepatide, the active ingredients in Wegovy and Zepbound, respectively. And a 2024 study suggested a potential link between semaglutide and the rare eye condition nonarteritic anterior ischemic optic neuropathy (NAION), in which restricted blood flow to the optic nerve causes sudden-onset vision loss. 'None of these studies are definitive in identifying that there has been a change. Some of them show a slight increase, but we're talking about a handful of patients who might have an increase in retinopathy compared to the millions of patients on these medications,' Kaden said. 3 In older people, AMD is a leading cause of irreversible blindness. StockPhotoPro – Researchers think that declining blood glucose levels caused by GLP-1s could trigger abnormal blood vessel growth in the retina. Further, there are GLP-1 receptors in the retina, and these drugs increase the levels of molecules that lead to harmful blood vessel formation. 'Seeing such a clear signal in our study was striking,' co-author Reut Shor of the University of Toronto told STAT. 'The absolute risk remains low, but the advanced form of AMD is a condition with serious implications for vision and quality of life. So a doubling of risk is clinically meaningful, particularly for vulnerable populations like older adults who may already be at elevated baseline risk.' Shor and his team note that more research is necessary to determine whether direct or indirect effects are causing the increased risk of nAMD. Shor and Kaden maintain that these findings should not be cause for alarm nor a reason to halt the prescription or use of these medications; rather, patients should be made aware of the risk and monitor their vision accordingly. Kaden, the study authors, and other experts recommend that GLP-1 users be on the lookout for any vision changes that could indicate early signs of AMD. 'We really want you to look for anything blurring, any new distortion. If you're looking at a flagpole or a doorframe, that should be a straight line. If all of a sudden that line looks wavy or curvy, that's a reason to seek a consultation with a retina specialist,' said Kaden.
